DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của Cara Therapeutics Inc

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors. Its lead product candidate includes intravenous CR845, which has completed Phase 2 clinical trials for the treatment acute postoperative pain in adult patients, as well as in Phase 2 clinical trials for the treatment of uremic pruritus disease.

TÊN CÔNG TY / COMPANY
Cara Therapeutics Inc

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
CARA

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare